|Security||FTK / Flotek Industries Inc. (343389102)|
|Industry||Miscellaneous Chemical Products|
|Common Shares Outstanding||56,958,671 shares (as of 2018-06-30)|
Stock Insider Trading (from SEC Form 4)
Flotek Industries Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
FTK / Flotek Industries Inc. insiders include SNIVELY JOSHUA A, Bodnar Robert C, Schmitz Robert M., Nierenberg David Hardy Carla S., REEVES STEVEN A, Marietta Matthew B, and Brown Ted D, REILAND JOHN, Cooper L Melvin, CHISHOLM JOHN, Adams Michelle M, Walton H. Richard, McGuire LV, Richard Katherine T., Hern Kenneth, .
Richard Katherine T.
Marietta Matthew B
Walton H. Richard
SNIVELY JOSHUA A
Brown Ted D
Adams Michelle M
Cooper L Melvin
Bodnar Robert C
REEVES STEVEN A
Hardy Carla S.
Schmitz Robert M.
Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.
|4||Richard Katherine T.||A||D||40,850||40,850|
|4||SNIVELY JOSHUA A||P||D||3.4073||4,450||455,516||1,552,080|
|4||SNIVELY JOSHUA A||P||D||3.4035||5,766||451,066||1,535,203|
|4||Walton H. Richard||P||D||3.3842||20,000||276,547||935,890|
|4||Marietta Matthew B||P||D||3.3558||6,850||94,975||318,717|
|4||Cooper L Melvin||A||D||3.74||33,423||137,868|
|4||Adams Michelle M||A||D||3.74||33,423||56,512|
|4||Brown Ted D||A||D||3.74||33,423||76,649|
|4||SNIVELY JOSHUA A||A||D||6.13||49,000||445,300|
|4||SNIVELY JOSHUA A||A||D||6.13||75,000||396,300|
|4||Marietta Matthew B||A||D||6.13||25,125||88,125|
|4||Marietta Matthew B||A||D||6.13||60,000||63,000|
|4||Walton H. Richard||A||D||6.13||25,313||256,547|
|4||Walton H. Richard||A||D||6.13||30,000||231,234|
|4||SNIVELY JOSHUA A||A||D||5.85||44,904||321,300|
|4||Walton H. Richard||A||D||5.85||36,667||201,234|
|4||SNIVELY JOSHUA A||F||D||4.66||-9,373||276,396|
|4||Bodnar Robert C||F||D||5.29||-5,823||76,955|
|4||REEVES STEVEN A||F||D||8.94||-43,828||295,095|
|4||Cooper L Melvin||F||D||9.72||-7,716||104,445|
|4||Cooper L Melvin||M||D||8.29||9,047||112,161|
|4||Hardy Carla S.||A||D||11.75||10,639||416,633|
|4||Brown Ted D||A||D||11.75||10,639||43,226|
|4||Cooper L Melvin||A||D||11.75||10,639||103,114|
|4||Adams Michelle M||A||D||11.75||10,639||23,089|
|4||REEVES STEVEN A||F||D||12.49||-169,325||341,565|
|4||REEVES STEVEN A||M||D||9.19||200,000||510,890|
|4||Schmitz Robert M.||D||D||-18,976||52,617|
|4||REEVES STEVEN A||A||D||68,333||310,890|
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Related News Stories
Flotek Industries (FTK) provides chemistry and services that are used in the oil and gas industries and in the consumer and industrial markets. In 2018, so far, Flotek Industries' stock price has dipped by 53%, while VanEck Vectors Oil Services ETF (OIH) declined 4%. OIH represents the oilfield equipment & services (or OFS) industry. FTK has some near-term challenges from the operational perspective as well as some structural headwinds. (13-1)
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (150-3)
Investors in Flotek Industries, Inc. (FTK - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 17, 2018 $3.00 Put had some of the highest implied volatility of all equity options today. (12-0)
Good morning, and welcome to the Flotek Industries Incorporated Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. This conference is being recorded. (12-0)
as of ET